Postpartum Tdap vaccination remains common despite ACIP recommendation
Recent data showed an increased rate of postpartum Tdap vaccination coverage, despite recommendations by the Advisory Committee on Immunizations Practices in 2011 to administer the vaccine during pregnancy.
“In October 2012, ACIP expanded the 2011 recommendation, advising pregnant women to be vaccinated with Tdap during each pregnancy to provide maternal antibodies for each infant,” investigator Indu B. Ahluwalia, PhD, MPH, from the CDC's National Center for Chronic Disease Prevention and Health Promotion, and colleagues wrote. “The optimal time for vaccination is at 27 to 36 weeks’ gestation as recommended by ACIP.”
The researchers studied results from the CDC’s Pregnancy Risk Assessment Monitoring System survey that queried women (n = 6,852) from 16 states and New York City who had a live birth from September through December 2011 about their Tdap status.
Results showed the median percentage of women who reported any Tdap vaccination (n = 5,499) was 53.4%, including 13.9% of the time before pregnancy, 9.7% during pregnancy and 29.8% after delivery.
Data also demonstrated that postpartum Tdap vaccinations occurred more frequently with non-Hispanic white women, those who started prenatal care in the first trimester, and those who had private health insurance coverage. In addition, Tdap vaccination coverage was lower for non-Hispanic black women, those starting prenatal care after the first trimester, and those with Medicaid coverage.
Researchers suggested that an aggressive information campaign, similar to the H1N1 influenza pandemic response, is necessary to improve Tdap coverage.
The researchers also said that “shortly after being recommended during pregnancy in June 2011, Tdap vaccination coverage during pregnancy was low; however, those results might reflect only the first few months of full implementation of the recommendation, which was published by CDC in October 2011. In contrast, this report assessed coverage among women delivering a live-born infant during September to December 2011. Thus, results in this report might provide a baseline for evaluating implementation of the current Tdap recommendations for pregnant women.” – by David Costill
Disclosure: The researchers report no relevant financial disclosures.